Company Overview and News

 
China nuclear power shares fall on Fujian tariff cuts, analysts say cuts may spread

2017-07-31 scmp
The price cuts are aimed at allowing nuclear power generators to compete better with coal-fired power generators, amid Beijing’s push for greater use of clean energy

 
Huadian Fuxin boss sees higher profit this year amid power pricing pressure

2017-03-27 scmp
Huadian Fuxin Energy, the alternative energy unit of China Huadian Group – one of the nation’s big five power generators – is expected to see profit growth continue this year despite ongoing pressure on power prices, according Fuxin chairman Fang Zheng.

 
China’s Huadian Fuxin looks overseas for new clean energy investments

2017-01-08 scmp
Energy group Huadian Fuxin is scouting overseas projects for growth amid slumping industry profits, and dimming opportunities in China’s capacity-glutted market

 
10 killed, 31 still missing in China’s landslide

2016-05-09 freepressjournal.in
Beijing: At least 10 people have been killed while 31 others remain missing in a massive landslide that engulfed the construction site of a hydropower station in China’s southeastern Fujian Province.

 
China’s Huadian Fuxin will slow wind farm expansion and seek power-swap deals

2016-04-04 scmp
Huadian Fuxin Energy, — the renewable energy unit of one of China’s biggest state-owned power generators China Huadian Group — will slow wind-farm installations due to ongoing power-grid bottlenecks.

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...